LOADING
Comparing Johnson & Johnson (JNJ) and Pfizer Inc (PFE), both in the Health Care sector. This side-by-side analysis covers price, valuation multiples, profitability, growth, dividends, and risk metrics to help investors evaluate these two stocks.
| Metric | JNJ | PFE |
|---|---|---|
| Price | -- | -- |
| Change Today | +0.00% | +0.00% |
| Market Cap | $651.3B | $158.4B |
| P/E Ratio | 31.1 | 36.6 |
| Forward P/E | 22.9 | 9.6 |
| PEG Ratio | 4.68 | 2.73 |
| EPS | $8.70 | $0.76 |
| Revenue Growth (YoY) | 6.6% | 2.6% |
| Profit Margin | 21.5% | 6.8% |
| Return on Equity | 25.7% | 5.0% |
| Dividend Yield | 1.96% | 6.09% |
| Beta | 0.23 | 0.28 |
| 52-Week High | $276.47 | $28.44 |
| 52-Week Low | $170.33 | $22.03 |
| Volume | -- | -- |
Johnson & Johnson is the larger company by market capitalization. Johnson & Johnson trades at a lower P/E ratio, suggesting it may offer better value relative to earnings. Pfizer Inc offers a higher dividend yield for income investors. Johnson & Johnson has stronger profit margins. Both stocks should be evaluated in the context of your investment goals, risk tolerance, and portfolio diversification needs.